Sanofi (SNY) Competitors $50.24 +0.11 (+0.21%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNY vs. NVO, NVS, AZN, GSK, TAK, ARGX, ONC, BNTX, SMMT, and INSMShould you be buying Sanofi stock or one of its competitors? The main competitors of Sanofi include Novo Nordisk A/S (NVO), Novartis (NVS), AstraZeneca (AZN), GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Summit Therapeutics (SMMT), and Insmed (INSM). These companies are all part of the "pharmaceutical products" industry. Sanofi vs. Its Competitors Novo Nordisk A/S Novartis AstraZeneca GSK Takeda Pharmaceutical argenex BeOne Medicines BioNTech Summit Therapeutics Insmed Novo Nordisk A/S (NYSE:NVO) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability. Which has preferable earnings & valuation, NVO or SNY? Novo Nordisk A/S has higher earnings, but lower revenue than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovo Nordisk A/S$42.12B7.60$14.64B$3.3821.22Sanofi$44.46B2.77$6.02B$2.8017.91 Is NVO or SNY more profitable? Novo Nordisk A/S has a net margin of 34.52% compared to Sanofi's net margin of 14.56%. Novo Nordisk A/S's return on equity of 80.94% beat Sanofi's return on equity.Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S34.52% 80.94% 24.23% Sanofi 14.56%17.15%9.80% Which has more volatility and risk, NVO or SNY? Novo Nordisk A/S has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Is NVO or SNY a better dividend stock? Novo Nordisk A/S pays an annual dividend of $1.64 per share and has a dividend yield of 2.3%. Sanofi pays an annual dividend of $1.60 per share and has a dividend yield of 3.2%. Novo Nordisk A/S pays out 48.5% of its earnings in the form of a dividend. Sanofi pays out 57.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Does the media refer more to NVO or SNY? In the previous week, Novo Nordisk A/S had 21 more articles in the media than Sanofi. MarketBeat recorded 43 mentions for Novo Nordisk A/S and 22 mentions for Sanofi. Novo Nordisk A/S's average media sentiment score of 1.19 beat Sanofi's score of 0.98 indicating that Novo Nordisk A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 33 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Sanofi 12 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate NVO or SNY? Novo Nordisk A/S presently has a consensus price target of $112.00, indicating a potential upside of 56.18%. Sanofi has a consensus price target of $61.50, indicating a potential upside of 22.61%. Given Novo Nordisk A/S's higher probable upside, analysts clearly believe Novo Nordisk A/S is more favorable than Sanofi.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novo Nordisk A/S 2 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.27Sanofi 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.11 Do insiders and institutionals hold more shares of NVO or SNY? 11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by company insiders. Comparatively, 1.0% of Sanofi shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryNovo Nordisk A/S beats Sanofi on 12 of the 19 factors compared between the two stocks. Get Sanofi News Delivered to You Automatically Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNY vs. The Competition Export to ExcelMetricSanofiLarge Cap Pharma IndustryMedical SectorNASDAQ ExchangeMarket Cap$122.91B$258.98B$5.72B$9.52BDividend Yield3.19%2.82%4.60%3.99%P/E Ratio17.9027.9528.0720.02Price / Sales2.775.05462.58104.32Price / Cash9.4114.1136.5558.97Price / Book1.5117.988.645.90Net Income$6.02B$8.49B$3.24B$258.50M7 Day Performance3.81%3.43%4.08%2.12%1 Month Performance4.94%3.42%10.68%12.62%1 Year Performance-5.54%-5.93%34.47%19.25% Sanofi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNYSanofi3.5194 of 5 stars$50.24+0.2%$61.50+22.4%-2.1%$123.24B$44.46B17.9582,878Upcoming EarningsNVONovo Nordisk A/S4.2334 of 5 stars$64.96+1.0%$112.00+72.4%-46.2%$290.05B$42.12B19.2277,349Positive NewsNVSNovartis1.5831 of 5 stars$114.18-0.1%$123.67+8.3%+7.4%$241.20B$50.32B16.6275,883Positive NewsAZNAstraZeneca2.9476 of 5 stars$68.72-0.1%$89.00+29.5%-7.6%$213.12B$54.07B27.6094,300Upcoming EarningsGSKGSK1.7302 of 5 stars$36.21-0.3%$37.38+3.2%-2.8%$74.12B$40.10B18.6668,629Upcoming EarningsAnalyst RevisionTAKTakeda Pharmaceutical1.6965 of 5 stars$14.46+0.2%N/A+8.0%$45.99B$30.09B65.7147,455Upcoming EarningsHigh Trading VolumeARGXargenex3.6803 of 5 stars$566.14+0.3%$728.06+28.6%+27.4%$34.65B$2.25B34.931,599Upcoming EarningsAnalyst RevisionONCBeOne Medicines1.2888 of 5 stars$291.93-0.9%$327.56+12.2%N/A$32.00B$3.81B-78.4811,000Insider TradeGap DownBNTXBioNTech1.4251 of 5 stars$108.91-1.0%$136.58+25.4%+37.8%$26.18B$2.98B-32.036,772News CoverageSMMTSummit Therapeutics2.1494 of 5 stars$26.34+0.5%$34.67+31.6%+176.3%$19.56B$700K-77.47110Positive NewsINSMInsmed3.9455 of 5 stars$102.78+0.2%$108.47+5.5%+39.1%$19.50B$363.71M-17.271,271Positive NewsAnalyst ForecastInsider Trade Related Companies and Tools Related Companies NVO Alternatives NVS Alternatives AZN Alternatives GSK Alternatives TAK Alternatives ARGX Alternatives ONC Alternatives BNTX Alternatives SMMT Alternatives INSM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNY) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanofi Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanofi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.